{"metadata": {"organization_names": ["magen by lilly", "magen", "magen but magen"], "person_names_verified": ["barclay kamb", "lester j. fagen", "magen. lilly"], "organization_names_verified": ["magen biosciences inc.", "magen biosciences inc", "business development of lilly", "lilly corporate center", "magen biosciences", "magen technology", "the magen technology", "magen and lilly", "magen biosciences, inc.", "cooley godward kronish"], "topics": [], "entities_rejected": [], "person_names": [], "agreement_id": "7f062ee399e69557f1cf33a96ec16f9fed3b56de5dc1c56a5d954fb3cd62e991", "vars": {"Party": {"ELI LILLY": "[[Party 1]]"}}, "terms": ["** (***\u201c", "***[rest of page left blank; signature page to follow]***", "***\u201cAgreement\u201d***", "***\u201cDisclosing Party\u201d***", "***\u201cEffective Date\u201d***", "***\u201cForce Majeure\u201d***", "***\u201cIndemnifying Party\u201d***", "***\u201cIndemnitee\u201d***", "***\u201cMagen\u201d***", "***\u201cNDA\u201d***", "***\u201cPatent Responsibilities\u201d***", "***\u201cReceiving Party\u201d***", "***\u201cRegulatory Documents\u201d***", "***\u201cRemedies\u201d***", "***\u201cSEC\u201d***", "**.**", "**Additional Compound Option.**", "**Additional Compounds**", "**Adverse Event Reporting.**", "**Amendment.**", "**Application Date**", "**Application Number**", "**Assignability.**", "**Audits.**", "**By Lilly.**", "**By Magen.**", "**Compliance with Law.**", "**Conduct and Funding**", "**Conduct of Defense.**", "**Confidential Information.**", "**Cooperation.**", "**Country**", "**Covenant Not to Sue**", "**Defense of Action.**", "**Development Reporting.**", "**Disclosure of Agreement.**", "**EXCLUSIVE LICENSE AGREEMENT**", "**Encumbrance**", "**Entire Agreement.**", "**Exclusive Use of Licensed Compounds by Magen.**", "**Exclusivity Regarding Dermatology Applications for VDRMs.**", "**Force Majeure.**", "**Governmental Filings.**", "**IN WITNESS WHEREOF,**", "**Indemnitee\u2019s Separate Counsel.**", "**Independent Contractor.**", "**Initial License Fee****", "**License Authority.**", "**License.**", "**Licensed Compounds**", "**Lilly Patents**", "**Lilly Warranties.**", "**Limited Disclosure Permitted.**", "**MAGEN BIOSCIENCES, INC.**", "**Magen Right of First Refusal Option**", "**Milestone Event**", "**Milestone Payment**", "**Milestone Payments.**", "**NOW, THEREFORE,**", "**No Benefit to Others.**", "**No Debarment.**", "**Notice.**", "**Notices.**", "**Patent Cooperation.**", "**RECITALS**", "**Record Retention, Royalty Reports, and Royalty Payment Schedule.**", "**Regulatory Matters.**", "**Representatives and Assistance.**", "**SCHEDULE A**", "**SCHEDULE B**", "**SCHEDULE C**", "**Schedule A \u0096 Licensed Compounds**", "**Schedule B \u0096 Additional VDRM Compounds**", "**Settlement.**", "**Severability.**", "**Sublicenses.**", "**Supply of Compound.**", "**Survival.**", "**THIS EXCLUSIVE LICENSE AGREEMENT**", "**Technology and Materials Transfer.**", "**Term.**", "**Trademarks.**", "**Transfers Related to Regulatory Matters.**", "**Transition Support.**", "**Waiver.**", "**[*", "**[[Date 1: Date]]**", "**and**", "**between**", "**\u201cAdditional Compound Option\u201d**", "**\u201cAdditional Compound\u201d**", "**\u201cAffiliate\u201d**", "**\u201cApplicable Laws\u201d**", "**\u201cCalendar Quarter\u201d**", "**\u201cClinical Trial(s)\u201d**", "**\u201cConfidential Information\u201d**", "**\u201cControl\u201d**", "**\u201cDamages\u201d**", "**\u201cData Exclusivity Period\u201d**", "**\u201cDevelopment Plan\u201d**", "**\u201cDiligent Efforts\u201d**", "**\u201cEffective Date\u201d**", "**\u201cFDA\u201d**", "**\u201cField\u201d**", "**\u201cFirst Commercial Sale\u201d**", "**\u201cForce Majeure\u201d**", "**\u201cGAAP\u201d**", "**\u201cInformation\u201d**", "**\u201cLicensed Compound\u201d**", "**\u201cLicensed Product\u201d**", "**\u201cLilly Know-How\u201d**", "**\u201cLilly Patents\u201d**", "**\u201cMAA\u201d**", "**\u201cMagen Technology\u201d**", "**\u201cMarketing Application\u201d**", "**\u201cNet Sales\u201d**", "**\u201cPatents\u201d**", "**\u201cPermitted Seller\u201d**", "**\u201cPerson\u201d**", "**\u201cPhase I Clinical Trials\u201d**", "**\u201cPhase II Clinical Trials\u201d**", "**\u201cPhase III Clinical Trials\u201d**", "**\u201cRegulatory Approval\u201d**", "**\u201cRegulatory Documents\u201d**", "**\u201cRoyalty Term\u201d**", "**\u201cTerritory\u201d**", "**\u201cThird Person\u201d**", "**\u201cValid Claim\u201d**", "*Wall Street Journal*", "*]      [*", "*] (*", "*] ([*", "*] (including at least [*", "*] day exercise period, or (iii) the Parties fail to successfully negotiate and execute a licensing agreement for the Follow-On Compound, in the case Magen has exercised such Follow-On Option, then Lilly shall be free to license the applicable Follow-On Compound to a Third Party, *", "*] days after the Effective Date. Thereafter, during the term Lilly will grant Magen access, during normal business hours, to appropriate Lilly personnel (including [*", "*] dollars ($[*", "*] given their schedules and other responsibilities to Lilly. [*", "*] million      [*", "*] million to $[*", "*] per calendar year so as to verify the accuracy of the information previously reported to Lilly under Section 4.4. Any such audit shall be conducted by an independent certified public accounting firm of national standing selected by Lilly and approved by Magen (which firm may be Magen\u2019s independent certified public accounting firm), such approval not to be unreasonably withheld. Such audit may cover the period back to the beginning of two (2) full calendar years preceding the date of the request for such audit and may not cover any prior period. Lilly may audit a given period of sales [*", "*] percent ([*", "*] to $[*", "*]% of such payment against the royalties payable to Lilly with respect to such Licensed Product, provided that in no event will the applicable royalty payable to Lilly with respect to such Licensed Product be reduced by more than [*", "*]%) of such amount owed, then the cost of the audit will be borne by Magen. Within [*", "*]) for reasonable consultation related to the Lilly Know-How not to exceed [*", "*]) hours (in two hour increments) in total. If Magen requests consultation (by telephone or videoconference) beyond this amount, Lilly will consider Magen\u2019s request in light of the availability of Drs. [*", "*]) or [*", "*]) or in at least [*", "*], [*", "*]; however, if as a result of such audit the Parties agree that the actual amount of royalties owed to Lilly, for the period audited, is more than the amount of royalties paid by Magen for the period that is the subject of the audit by greater than [*", "*bona fide*", "*e.g.*", "*except for*", "*provided that*", "*provided, however,*", "\u201c**Phase IIb Clinical Trials**\u201d", "\u201cAdditional Compound Option\u201d", "\u201cCode\u201d", "\u201cFailed Product\u201d", "\u201cFollow-On Compounds\u201d", "\u201cFollow-On Option\u201d", "\u201cMagen Exclusivity Period\u201d", "\u201cReplacement Product\u201d", "\u201cThird Party License\u201d", "\u201cTransferee\u201d", "\u201cTransfer\u201d ) all or a part of, Lilly\u2019s rights to the royalty payment and other payments referred to in Article 4 (the \u201cPayment Rights\u201d", "\u201ccontrolled by\u201d and \u201cunder common control with\u201d", "\u201d***", "\u201d*** and collectively as ***\u201c", "\u201d***), a corporation organized and existing under the laws of the State of Indiana, having its principal place of business at Lilly Corporate Center, [[Address 2: Address]]. Magen and Lilly may be referred to herein individually as a ***\u201c"]}}